Creative medical staff holds 40% ( 58.605mil)of the total celz o/s on june4 2017.
The PPS was 0.3 at the date of acquisition which was valued at 17.4 mil usd.
Celz is at the last stage of the clinical trial...which is also the most critical N easiest stage of the 4 phases.
CELZ is at the final stage of the clinical Phase IV studies,--- often called Post Marketing Surveillance Trials, are conducted after a drug / procedure / device has been approved for consumer sale.
Pharmaceutical companies have several objectives at this stage:
(1) to compare a drug with other drugs already in the market;
(2) to monitor a drug's long-term effectiveness and impact on a patient's quality of life; and
(3) to determine the cost-effectiveness of a drug therapy relative to other traditional and new therapies.
This is also the most costly phase of R& D Human Clinical Trial Phases..
(Which is also why most investors tend to pull their investment out prior this phase because this phase requires constant infusion of cash....thats why we saw some serious profit taking around Dec 17.)
IT NEEDS TO RAISE CAPITAL TO COMMERCIALIZE ITS PRODUCTS/ PATENTS.
----That is why CELZ has applied for special exception Confidential Treatment Order ( C.T.O.) on march 2 2018--The reason is to omit certain information from their required filings they can complete a confidential treatment order request, which is reviewed by the SEC. The request must contain the information the company is looking to withhold and the time period the company is looking to withhold the information. This CTO is also a strong indication 30 days period to review and approaching completion of phase 4.
Companies would typically seek a confidential treatment order (CTO) to keep information secret that would otherwise put it at a competitive disadvantage if revealed. A company would seek the confidential treatment order by filing a formal request, a confidential treatment request (CTR), with the Securities and Exchange Commission (SEC).
The Company has acquired a royalty license from Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (“LABIOMED”) granting the exclusive license to the products and services of a LABIOMED patent.
Creative Medical is engaged in stem cell research and applications for use to treat male and female sexual dysfunction, infertility and related issues. It holds a patent for its erectile dysfunction ("ED") treatment and was granted a license by Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, a non-profit biomedical research and education institute ("LABIOMED"), for the infertility treatment. It has also filed a patent application focused on physical manifestations of female sexual arousal disorder, as an extension of the work with stem cell therapies for ED. Following testing of its ED treatment, Creative Medical intends to market treatment kits to physicians for use with their patients suffering from ED.
During first quarter 2016, it commenced a 15-month clinical trial study being conducted at UCLA by LABIOMED on the efficacy and safety of the ED treatment. The study involves testing on 40 subjects. Following further testing, Creative Medical also intends to market licensed products under its infertility technology license and the female sexual dysfunction patent application.<-----PHASE 4
I think we are approaching the final period of completing the phase 4.
Celz is looking good.
PR and update can be anytime now.
GLTA
GLTA
